Virpax Pharmaceuticals (NSDQ:VRPX) announced today that it priced an underwritten public offering worth approximately $40 million.
Berwyn, Pennsylvania-based Virpax’s offering includes 6.67 million shares of common stock priced at $6 per share, totaling just over $40 million before deducting underwriting discounts and offering expenses.
Get the full story at our sister site, Drug Delivery Business News.